Medicaid's Expenditures for Newer Pharmacotherapies for Adults with Disabilities
暂无分享,去创建一个
[1] S. Rigler,et al. The Cost Effect of Newer Medication Adoption in an Older Medicaid Cohort , 2005, Journal of the American Geriatrics Society.
[2] S. Soumerai. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. , 2004, Health affairs.
[3] Evaluating and Improving Physician Prescribing , 2002 .
[4] Mary Chatfield,et al. Health Care Financing Review , 1980 .
[5] K. Kupka,et al. International classification of diseases: ninth revision. , 1978, WHO chronicle.
[6] S. Majumdar,et al. Evaluating and Improving Physician Prescribing , 2002 .
[7] R. Stafford,et al. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.
[8] S. Sullivan,et al. States' control of prescription drug spending: a heterogeneous approach. , 2005, Health affairs.
[9] H. Goldman,et al. Mental health policy and psychotropic drugs. , 2005, The Milbank quarterly.
[10] P. Pine,et al. Medicaid Prescription Drug Spending in the 1990s: A Decade of Change , 2004, Health care financing review.
[11] Hhs Centers for Medicare Medicare Services. Medicare program; Medicare prescription drug benefit. Final rule. , 2005, Federal register.